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Microfluidic systems aim to detect sample matter quickly with high sensitivity and resolution, 
on a small scale. With its increased use in medicine, the field is showing significant promise in 
prostate cancer diagnosis and management due, in part, to its ability to offer point-of-care 
testing. This review highlights some of the research that has been undertaken in respect of 
prostate cancer and microfluidics.  
 
Methods 
Firstly, this review considers the diagnosis of prostate cancer through use of microfluidic 
systems and analyses the detection of prostate specific antigen, proteins, and circulating 
tumour cells to highlight the scope of current advancements.  
Secondly, this review analyses progressions in the understanding of prostate cancer 
physiology and considers techniques used to aid treatment of prostate cancer, such as the 
creation of a micro-environment.  
Finally, this review highlights potential future roles of microfluidics in assisting prostate 
cancer, such as in exosomal analysis.  
 
Conclusion 
In conclusion, this review shows the vast scope and application of microfluidic systems and 




























Microfluidics is the study of systems that can perform analysis on microscopic quantities of 
fluid using equipment on a micrometre scale. Due to adapted fabrication techniques for 
silicon processing from the electronics industry, the microfluidic system is also commonly 
referred to as a microfluidic chip. A microfluidic chip contains features which have at least 
one linear dimension in the submillimetre diapason. In terms of volume such miniaturisation 
translates into microlitre, nanolitre or picolitre volumes of fluid processed on-chip at a time. 
One immediate consequence of using small volumes is the reduction of sample and reagent 
consumption per assay, thus making the analysis more affordable and environmentally 
friendly than the conventional detection methods. Miniaturisation in microfluidics also leads 
to process intensification due to surge in surface-to-volume ratio and decrease of diffusion 
times, which essentially facilitates faster analysis. Typically, five core components are 
required in a fully integrated microfluidic system to allow for autonomous analysis: sample 
introduction, movement, purification, detection and analysis (1). Microfluidic systems aim to 
detect sample matter quickly with high sensitivity and resolution, while significantly reducing 
the invasiveness of sample collection and volume of the analysis. This, coupled with the small 
scale of equipment used, the high level of automation and its relatively cheap production, is 
leading to an increase in its use in medicine (2, 3).  
 
In addition, the field of microfluidics is showing significant promise in cancer diagnosis and 
management (4, 5). Analysis of urine, blood, and other tissue fluids on a microfluidic scale has 
yielded detection of circulating tumour cells and cancer specific biomarkers, as well as 
permitting growth and study of tissue on a single cell level.  
 
Prostate cancer is the third most common cancer in the United Kingdom and second most 
common cause of cancer death in men (6, 7). The current gold standard for prostate cancer 
diagnosis is the invasive method of transrectal ultrasound guided biopsy (8). There is a 
significant amount of debate currently taking place internationally regarding a screening 
process for prostate cancer, as it is known that early prostate cancer diagnosis is pivotal in 
ensuring increased survival rates through simple and effective treatment (9). However, 
biomarkers for prostate cancer can be non-specific. Sensitive microfluidic detection systems, 
with their ability to detect clinically significant levels of certain markers with just small 
quantities of fluid, together with a small size permitting point of care testing, may be able to 
offer instantaneous cancer diagnosis and as such, revolutionise cancer screening. Microfluidic 
systems may prevent a patient from the morbidity associated with prostate biopsies and 
allow for appropriate diagnosis, as well as to encourage further study to assist with cancer 
management (10). Furthermore, in noting recent developments to cope with the evolving 
coronavirus pandemic, such as the recommendations for remote consultations and only 
performing high priority or emergency surgery, a system that avoids the need for biopsy and 
minimal patient contact may prove helpful (11).  
 
This review seeks to summarise past and ongoing microfluidic prostate cancer research to 
identify key advancements in detection, therapeutics, and physiological understanding. 
 
For this review, PubMed was used to search for citations as electronic resources. The 
database was searched with no restrictions on language, date published or country of origin. 
We used database specific combinations for the terms ‘prostate’ and ‘microfluid’ to appear in 
the paper title. Further papers were subsequently chosen to help elaborate on these papers, 
as well as to show potential future directions of research. 
 
Prostate Specific Antigen  
 
Prostate specific antigen (PSA), is a protein biomarker that has been found to be the single 
most significant and clinically used predictive factor for identifying men at increased risk of 
prostate cancer (12, 13). Evidence suggests that a PSA level of 4ng/mL or higher is clinically 
significant in cancer biopsy and a level less than 0.4ng/mL, or even ≥ 0.2ng/L checked with a 
second confirmatory level, is significant in monitoring for cancer recurrence after radical 
prostatectomy (14-17). Some studies even suggest that the exact figure is not important, but 
a rising PSA of two or more subsequent occasions is a better determinant (18). However, PSA 
levels are also increased in a variety of other, non-malignant prostate conditions, including 
prostatitis and benign prostatic hyperplasia (19). Therefore, much research has occurred into 
the microfluidic detection of PSA to both increase the ability to detect PSA from small fluid 
quantities and to enhance diagnostic ability, through differentiation of PSA more indicative of 
cancer.  
 
Microfluidic platforms for prostate specific antigen diagnostics 
Detection of PSA using microfluidics began in 2007, and the intention was to improve upon 
the commonplace use of the Enzyme Linked Immunosorbent Assay (ELISA). Initial studies 
used an immobilised anti-PSA antibody attached to a horseradish peroxidase enzyme. When 
activated by PSA, in the presence of hydrogen peroxide, this enzyme catalyses the oxidation 
of 4-tert-butylcatechol, which can then be quantified. This method of PSA detection showed 
a detectable response equivalent to the concentration of total PSA in the serum. As 
compared to ELISA, this microfluidic method revealed significant enhancement in sensitivity. 
Additionally, the overall assay time of this cost-effective method was 70 minutes shorter than 
the 100 minutes required for ELISA test kits, and resulted in no reduction in sensitivity (20).  
 
Three years later, Triroj et al. created a different design to a microfluidic chip to rival the 
earlier research (9). They used a system that generated a current proportional to the number 
of immune complexes created between PSA and a PSA antibody. Their system worked on the 
basis that PSA, from spiked buffer solution, would compete with a PSA-enzyme conjugate, on 
the microfluidic chip, for the binding site on an anti-PSA antibody. The release of the PSA 
enzyme-conjugate, after competitive replacement, caused a proportional reduction in 
electrical current on the microfluidic chip.  This method was able to detect PSA in just 7 
seconds and highlighted a promising approach in electrical PSA detection (9).  
 
Electric based detection methods were employed once again in 2019, when a portable, 
robust, low cost microfluidic device to sense PSA was generated. This device used a screen-
printed electrode coated with a glass solution using sol-gel based approach. It was able to 
detect PSA in human serum with concentrations as low as 1pg/L through 
chronoamperometry and square wave voltammetry. This microfluidic chip employed an anti-
PSA antibody fixed onto the surface of a gold electrode, so that chronoamperometry could 
be used to detect the electrochemical signals subsequently produced on PSA binding. 
Currents proportional to PSA concentrations were created with sensitivity and reproducibility 
(21). In contrast to the earlier method employed by Triroj et al., this technique used an 
increase in current as opposed to a decrease, providing capacity for a wider range of PSA 
concentrations. 
 
As a result of the opening of new avenues for microfluidic PSA detection, some teams have 
employed the use of aptamers, which are artificial capture probes of specifically designed 
sequences of nucleic acids, to detect specific proteins. The first team to apply aptamers in 
PSA detection used a novel, love-wave biosensing device on a polydimethylsiloxane 
microfluidic template, in an attempt to allow for highly sensitive and specific PSA detection 
(22).  However, this study, which relied on aptamer detection of PSA, only obtained a 
detection limit of 10ng/mL, which was not low enough for real sample detection. Thus, more 
work was required to permit point-of-care use as well as real time monitoring.  
 
Therefore, two years later, the concept of aptamers was used once again to create a 
magnetic controlled system that exhibited photocurrent response from PSA concentrations 
as low as 0.001ng/mL. This new technique released trigger DNA when PSA successfully bound 
an aptamer, and this subsequently caused the formation of a large amount of glucose 
oxidase. This glucose oxidase then reacted with a graphene oxide - bismuth ferrite 
combination to produce a quantifiable photocurrent in the microfluid system. This system 
was effectively employed to analyse PSA in human serum, displaying good accuracy with a 
low detection limit, highlighting a clear improvement to earlier aptamer trials (23).    
 
Outside of antigen-based detection mechanisms, research has taken place into the use of 
ultrasonic waves to separate PSA from whole blood samples. This use of these ultrasonic 
waves, coupled with a microfluidic channel was seen to appropriately assist in separation of 
plasma from whole blood, which could then be further analysed for PSA. Though this method 
was able to detect PSA at clinically relevant levels, it was limited by the multi-step nature of 
the method which  would not allow for point-of-care testing without further development 
(24). 
 
Microfluidic point-of-care testing 
The research methods described above were successful in a laboratory environment. 
However, to make microfluidic detection of PSA more accessible to patients and healthcare 
professionals, research was conducted by Barbosa et. al to enhance microfluidic PSA testing 
of whole blood using a smartphone device. Their research showed that an iPhone camera 
and fluorescence detection could be used to detect PSA in a clinically significant range from 
0.9 to 60ng/mL (25). However, the team noted that improvements were required in 
optimising the enzymatic reaction with the PSA, and that a more robust UV light source was 
required as opposed to an iPhone. Therefore, later in 2017, the same team did further work 
to enable point-of-care testing through use of a flat-bed scanner. The team engineered a 
microfluidic method to successfully highlight PSA at concentrations between 10-100ng/L, by 
using gold nanoparticles with silver enhancement conjugated to an anti-PSA antibody. 
Although this data set did show significant variability at higher PSA concentrations, direct 
optical detection was not possible without the use of enzymatic amplification or 
fluorophoresis. However, as this study utilised a flat-bed scanner, the team successfully 
showed continued activism in producing low cost point-of-care testing, although the team 
did also note that vast improvements were necessary to improve one step particle detection 
(26). 
 
Microfluidic detection of cancer specific prostate specific antigen 
Although many of the above mentioned methods show significant promise in PSA detection, 
they are of limited value, as the PSA detected is not specific for prostate cancer (19).  
However, there does exist research that is looking specifically at microfluidic PSA detection to 
identify prostate cancer. Gao et al, based in China, have shown significant promise since 2016 
in their use of microfluidics for PSA detection. This team utilised a Surface-Enhanced Raman 
Scattering (SERS) technique with microfluidics to successfully isolate and quantify PSA (27), 
and two years later were able to highlight the significance of their preliminary research.   
 
With the knowledge that a low level of free PSA, but a high total PSA highlights a person 
more at risk of prostate cancer, the team in China attempted to isolate these two forms of 
PSA in a dual microfluidic platform (28, 29). The technique of microfluidic detection of free 
and total PSA had previously been employed by Chiraco et al in 2013, who designed a 
microfluidic electrochemical impedance spectrography system that permitted detection of 
free and total PSA through use of two separate antibodies (30).   However, Gao et al, in 
contrast, used their earlier employed SERS technique to detect PSA in human serum through 
the creation of quantifiable magnetic immune complexes, to enable the clinically significant 
detection of both free and total PSA in samples in only 5 minutes (29). On the other hand, 
this study was on a small scale using only five samples from people with known prostate 
cancer and had a significant drawback in the use of an external pump which reduced the 
capacity for point-of-care testing. 
 
Consequently, further research was conducted by Gao et al to increase the capacity for point-
of-care testing. They designed a capillary pump on their microfluidic chip design to help 
reduce sensor size, improve reliability and to allow for sensitive and rapid detection of PSA. 
Though a new chip had to be loaded for each sample analysis, the PSA concentration was 
detected in a linear range, with ability to analyse below the clinically significant level of 
4ng/mL, in only 5 minutes, without an external pump. Thus the standard of their previous 
research to detect PSA levels with high sensitivity at concentrations as low as 0.01ng/L was 
maintained and a method more akin to point-of-care testing was created (31).  
 
Multiple detection targets 
To boost the accuracy of prostate cancer diagnostic tests, molecular targets such as miRNA as 
well as the proteins they code for, can be tested for at the same time as serum PSA (32, 33). 
As opposed to their simple detection alone, testing for these molecular targets, in addition to 
PSA, is thought to improve upon the limitations of a simple PSA assay. Though multiple 
detection targets have yet to be employed with PSA in microfluidic prostate cancer analysis, 
it is a route that could see much success moving forward.  
 
In 1999, Bussemakers et al. found the highly prostate cancer specific DD3 (differential display 
code 3) protein. This protein was not found in any other cell of the body aside from prostate 
cells and was found to exhibit an almost 100-fold overexpression in malignant areas 
compared to benign areas within the same prostate tissue. In contrast, PSA alone was not 
able to identify significant differences between benign and malignant tissue within the same 
prostate. The protein levels of DD3 were also found to directly correlate with cancer severity. 
Further work highlighted that the aetiology of this protein was a non-coding microRNA, found 
in prostate cells. Thus the presence of this protein and microRNA was highlighted to be a 
promising marker for both diagnosis and potential treatment of prostate cancer (34).  
 
Therefore in 2002, the same research team developed a method for accurate quantification 
of the miRNA responsible for DD3 protein creation using the reverse transcription 
polymerase chain reaction. As well as corroborating earlier results, the team showed that 
even in tissue with less than 10% tumour cells, DD3 miRNA expression was significantly 
increased. The expression of this miRNA was found to be much higher than some other 
upregulated proteins in cancer cells, such as those involved in telomerase activity. With such 
high levels of miRNA in tumour cells, the team predicted the presence of the miRNA would 
be advantageous in fluid detection even on a small scale; thus, showing possible applicability 
to microfluidics. Interestingly, the team were not able to find the functionality of the DD3 
protein and also found that there was no correlational activity of tumour stage with protein 
levels (35).  
 
Later research in California looked further into analysis and quantification of the gene 
encoding the DD3 prostate specific miRNA, which came to be known as Prostate Cancer Gene 
3 (PCA3). In this study, the PCA3 miRNAs and PSA mRNAs were collected and quantified in 
men undergoing prostate cancer biopsy and correlated with their prostate biopsy results. The 
two collected mRNAs were then put together to calculate a patient specific ratio. The 
specificity of this PCA3:PSA mRNA ratio, to detect prostate cancer, was found to be 79% as 
compared to 28% specificity for use of serum PSA levels alone. Therefore, this study showed 
that analysis of multiple detection targets enhances prostate cancer diagnosis, allowing for 
earlier treatment. The study also showed 89% specificity in detecting normal patients, 
reducing the need for over diagnosis, as currently seen with PSA. The study also showed 
applicability of cancer recurrence screening (36). 
 
Continuing with multiple detection targets, a study in India looked into the ratio of serum PSA 
as compared to the quantity of serum prostate secretory protein of 94 amino acids (sPSP94). 
Though the protein is not prostate specific, serum concentrations of sPSP94 are reflective of 
prostate secreted levels, with the study finding that concentrations were significantly lower 
in cancer patients as compared to those with benign conditions.  Using ELISA, the team 
highlighted that the ratio of these two serum proteins (PSA:sPSP94) enhanced the specificity 
of prostate cancer patient identification in a patient study by 70.45%. The ratio test using 
both proteins together was even more sensitive than either protein alone (37). Though this 
was an ELISA test, it is possible that a microfluidic chip may be able to perform similar 
functions. 
 
Given the success of these two studies, perhaps it is through the detection of multiple 
protein targets that microfluidics may be able to progress in its assistance with prostate 
cancer diagnosis and screening. 
 
As we can see, though significant research has been employed to detect PSA using 
microfluidics, studies looking at prostate cancer specific detection is lacking, aside from the 
most recent studies, and those that have begun to employ multiple detection targets that do 
not currently use microfluidics. Therefore, perhaps the detection of an alternative prostate 
cancer biomarker may yield more significant promise in prostate cancer developments.  
 
Circulating Tumour Cells 
 
Circulating Tumour Cells (CTCs), after being both actively and passively secreted from 
tumours,  enter blood vessels and can cause further metastases (38). The detection of these 
CTCs in patients allows for monitoring of cancer patients, as well as holding value in 
informing patients of prognosis and tailored treatment options (39).  CTCs can be cancer 
specific, and the ability to detect prostate cancer specific proteins on CTCs has shown 
significant benefit above non-specific PSA detection in identifying patients suffering from 
prostate cancer. Microfluidics is a method that has thus been employed to both detect and 
analyse CTCs specific to prostate cancer.  
 
Microfluidic detection of circulating tumour cells using antigens 
Prostate Specific Membrane Antigen (PSMA), also known as folate hydrolase, is a 
glycoprotein expressed at increased quantities by prostate cancer cells, including CTCs, and 
its levels have even been noted to increase with both androgen independence and cancer 
aggressiveness (40, 41).  In as early as 2009, a team in Louisiana attempted to use 
microfluidics to detect PSMA on CTCs using an immobilised anti-PSMA aptamer on a 
microfluidic chip. The aptamer was chosen because of its enhanced stability at room 
temperature as compared to antibodies. In this study, the prostate specific CTCs, after 
flowing through the microfluidic chip at optimal velocity, were counted by a conductivity 
sensor after release from the aptamer. Using this method, concentrations as small as 10 
cells/mL were detected. However, a comparatively large volume of 1mL of whole blood was 
required in this study, which is not quite in keeping with the true purpose of microfluidics 
(42).  
 
Building upon this method of PSMA detection, Esmael et al. designed an integrated 
permalloy-based microfluidic chip for the isolation of prostate cancer CTCs using an anti-
PSMA antibody. Using this chip, the team were able to detect prostate cancer cells with high 
sensitivity, using a magnetic separation method which had increased sensitivity at a micro-
scale once immune complexes had been formed. Though not a patient study, the team were 
able to detect clinically relevant concentrations of 20 cells/mL, at an acceptable throughput 
at 100 microlitres/minute, with almost 100% capture efficiency (43).  This same team 
continued their work in 2019 with the same permalloy-based microfluidic chip with the 
addition of a multi-orifice flow fractionation filter (MOFF). This addition helped to improve 
upon their previous attempt, as the MOFF acted to remove free magnetic beads from whole 
blood samples before entering the microfluid chip. Prostate CTCs at concentrations as low as 
5 cells/mL were captured in this study with up to 75% efficiency. The 100% magnetic capture 
ability was maintained in this second test, but this was also not a patient study (10). 
 
As opposed to magnetic capture, other microfluidic technology has been fabricated for the 
trapping of CTCs, such as a label free electrochemical immunosensor for PSMA detection. 
This technique, employed in 2017 using gold nanoparticles functionalised with anti-PSMA 
antibody, showed significant ability to detect only PSMA positive cells as compared to cells 
from normal prostate tissue, creating a sensitive and specific ability to detect PSMA positive 
cells akin to CTCs (44). These studies thus far, clearly show the relative ease by which 
microfluidics can be employed to capture PSMA positive CTCs. 
 
Moving forward from simple CTC detection, a team in New York after using microfluidics to 
detect CTCs, began to look at how this method could be used to aid therapeutics. Kirby et al 
utilised anti-PSMA antibodies on a geometrically enhanced immunocapture device to capture 
CTCs with high specificity towards PSMA+ cells. These CTCs were then treated with 
chemotherapeutic taxane agents such as docetaxel to monitor drug target engagement. The 
effects of docetaxel, in its actions to induce bundle formation through stabilising 
microtubules, could be readily detected by immunofluorescence staining. This experiment 
showed different responses of CTCs in prostate cancer patients who were docetaxel resistant 
and differential responses for a different taxane class – paclitaxel. This exciting research 
paves the way for monitoring drug target response and resistance through analysis of 
microfluid separated CTCs to optimise cancer treatment (45).  
 
Aside from PSMA, researchers have attempted to detect and analyse CTCs with other 
antigens. In 2015, Khamenehfar et al. used a microfluidic chip to detect CTCs based on their 
unique ATP-Binding Cassette Transporters (ABCs).  These ABCs provide cancer cells with 
multidrug resistance through their ability to actively transport therapeutic or toxic substances 
out of cells (46). The team were able to isolate CTCs whilst maintaining cell viability for 
further analysis, without using immune-affinity manipulations such as antibodies. Subsequent 
measurements could then be carried out on the isolated CTCs through inhibiting ABCs to 
analyse cellular affects, showing clear applicability to personalised patient centred medicine 
in the future (47). However, this study used mouse blood cells mixed with human prostate 
cancer cells to create a solution akin to CTCs and additionally the method assured no clear 
way of maintaining prostate cancer specificity in CTC separation. Although the study shows 
promise in principle, more work is clearly required. 
 
A subsequent method of prostate cancer isolation of CTCs using microfluidics, employed in 
2016, was immunofluorescence antibody staining for pancytokeratin, epithelial cell adhesion 
molecule and CD45. This research was performed on 50 patients undergoing radical 
prostatectomy for clinically localised prostate cancer only. Possible CTCs, via detection of 
these antigens, were detected in 50% of the patient cohort. The study did, however, 
acknowledge the uncertainty of whether the cellular matter detected were true CTCs or in 
fact malignant cells from the primary cancer.  Interestingly, this study highlighted no 
correlation of detection of CTCs with other pathological risk parameters such as PSA. The 
research team recognised that monitoring through this method, even in localised cancer, 
may be of value to help in monitoring for metastatic potential, as well as sample analysis to 
help guide therapy (48).  
 
Furthermore, a team based in Massachusetts who were also aware of the drawbacks of 
detection of CTCs using antigens alone created an innovative system to detect CTCs. The 
system created, involved the initial magnetic labelling of cells in whole blood before 
subsequently using a single microfluidic chip to separate, align and detect all cells 
appropriately. This study showed high sensitivity and specificity for detection of CTCs in 
prostate cancer patients, whilst allowing for a speed of 8mL per hour, with preservation of 
the cells for subsequent analysis. However, this system did rely on the fact that magnetic 
labelling was based on detection of three antibodies, so at least one form of these antigens 
was required to be present, for the system to positively identify a CTC (49).  
 
Due to difficulties of the specificity of antigen detection on CTCs, a team in Wuhan attempted 
to create a novel solution. Armed with the knowledge that CTCs can have different 
metastatic stages within the blood, partly due to epithelial-mesenchymal transition, the team 
constructed a dual antibody functionalised microfluidic device that employed antibodies both 
against PSMA and epithelial cell specific markers. This method enabled enhanced capture 
efficiency of CTCs as compared to a single antigen capture system and CTCs were correctly 
identified in 83% of prostate cancer patients. Furthermore, the cell count of CTCs through 
this method, could be correctly correlated to the pathological stage of a patient’s prostate 
cancer, which PSA levels alone could not do. Additionally, these isolated CTCs were not 
altered too much by their capture, and therefore could be further analysed to see their 
sensitivity to androgen deprivation therapy, immunotherapy, and metastatic potential. In this 
same study, it was also showed that PSMA expression was significantly higher in patients with 
cancer than those with benign prostatic hyperplasia and that PSMA expression was further 
increased in patients with a higher Gleason score or metastases (50).  
 
A dual approach to microfluidic detection of CTCs was also adopted in 2013 to isolate 
prostate cancer cells. The technique used detected PSMA, whilst also using dielectrophoresis 
to enhance the specific immunocapture of prostate cancer cells, through use of an 
alternating current. The dielectrophoresis could be used on the basis that almost all cancer 
cell types have a dielectrophoresis frequency that is notably different from blood cells (51).  
In using these two means of cancer cell detection simultaneously, this technique showed 
significant promise in synergistically assisting cancer cell capture. This study highlighted the 
ability to ensure both high capture efficiency as well as purity at specific frequencies, such as 
350kHz to isolate CTCs. The results were negatively influenced by the local shear stresses 
experienced by cells and the team did also acknowledge further work was necessary. 
However, this preliminary research enables further studies and research on metastasis and 
therapeutics (52, 53). 
 
Microfluidic detection of circulating tumour cells using mechanical properties 
Analysis of CTCs using biomarkers alone, such as antigens, can have significant drawbacks 
due to cellular change, thus indicating the need for other methods to detect prostate cancer 
CTCs.  Therefore Renier et al collected CTCs that had become de-differentiated and lost 
epithelial characteristics, as well as some that were undergoing developmental transition, 
using a microfluidic vortex chip, that separated cells based on size (54). The team were also 
able to show significant correlation between the PSA level and number of CTCs isolated by 
this method.  Additionally, unlike other methods available of separating cells based on size, 
this method kept cells viable and intact. However, this method did not isolate all CTCs and 
the research had a capture efficiency of approximately 24.5% of a prostate cancer specific 
cell group. Even considering this low capture efficiency, the team did conduct subsequent 
cellular analysis on the cells collected and highlighted that an antigen method for detection 
of CTCs is limited due to the changing nature of the cells. Thus, a method of label free 
isolation, or perhaps recognition of all possible antigens, may need to be employed to ensure 
sensitive capture of CTCs (54). 
 
Similarly, an international team in 2012, attempted to refine a mechanical method of 
recovering CTCs using three different free fluorescently immunolabelled prostate cancer cell 
lines within a mixture of white blood cells. The team were able to separate the CTCs based on 
size through ultrasonic acoustophoresis in rigid microfluidic channels whilst maintaining cell 
viability. The technique used three fundamental characteristics of size, density, and 
compressibility to aid cell separation. Their experiment was also enhanced by a novel pre-
alignment procedure that improved separation efficiency, and an optimal channel width in 
the microfluidic system. The team found that there was increased ability to retrieve cancer 
cells at higher acoustic energies. However, the team also found that recovery of cells varies 
based on the prostate cancer cell line used, and not all white blood cells could be removed 
entirely from the tumour cells, indicating that other cellular attributes such as mass density 
may also have a role in separation, which acoustophoresis alone could not separate. The 
team noted that refinement was required to enable detection of all CTCs at clinically relevant 
low concentrations of cells (55). 
 
Ren et al also attempted to separate CTCs based on specific biophysical properties, after 
noting the issue of antigen separation alone. Their study specifically looked at isolation of 
CTCs based on size and deformability. They used a microfluidic multiple row-based device 
that could trap cells with 96% efficiency, whilst retaining the cell shape. However, in this case, 
a specific prostate cancer cell line mixed with rodent whole blood was used, so further 
investigation is needed prior to patient tests. (56)  
 
In conclusion, with regard to CTCs, more work is required to ensure detection that is sensitive 
and specific to allow for effective reproducibility and marketability. For a microfluidic system 
to be safely used for screening, there would need to be a low false negative rate. With some 
CTCs undergoing transition and not displaying certain biomarkers, a more significant study on 
patients would be required using one of the methods employed above, or otherwise, to 
ensure patient safety. CTCs also have a significant drawback, in that unless they are being 
produced by a prostate cancer (i.e. it has metastatic potential) it may be of limited use. 
However, it is important to remember that once isolated these CTCs would have potentially 
limitless potential in enabling patient specific therapeutic tests and analysis.   
 
Microfluidics to aid with prostate cancer physiology and management 
 
Aside from detection of prostate cancer through means such as PSA and CTCs, vast amounts 
of research have been undertaken into using microfluidics to assess some specific aspects of 
prostate cancer, namely its physiology and management. 
 
Microfluidics and prostate cancer management 
In 2014, microfluidics was used to assess the effects of combination chemotherapy on a 
prostate cancer cell line in Korea. A microfluidic system was designed to both assist in drug 
screening against patient cells whilst helping in optimisation of drug concentrations, to not 
affect non-cancerous cells. A microfluidic high throughput drug screening program was 
created through a platform consisting of eight different concentrations of two chemo-
therapeutic agents to create 64 chambers with 64 varying concentrations of the two agents.  
This study utilised the two agents, curcumin (a natural component thought to enhance 
chemotherapy cell responsiveness) and tumour necrosis factor related apoptosis inducing 
ligand. The system had the benefits of low cost, not requiring continuous perfusion after the 
wells were appropriately filled, and reduced shear stress on the cells. This method was shown 
to produce valuable results on effective therapeutic concentrations and was proven to be 
more effective than using a well plate method to find optimal therapeutic concentrations for 
prostate cancer cell effect. The system also held significant advantages in the frequent 
replenishment of fresh media and drug solution. (57)  
 
Within the same year a team in Michigan used microfluidics to create a prostate cancer cell 
line clonal expansion before characterising sub-phenotypes to assess response to drug 
treatments. The technique offered advantages in comparison to the conventional cell assays 
which allowed only an average representation of cell lineage cell types at high cost and 
labour, whilst analysis on a smaller scale avoids this and the lineage of even a single cell from 
microwell in a microfluidic chip could be traced. The team were able to isolate single cells in 
the microfluidic chip, before studying them and the phenotypes of their progeny prior to 
assess their chemotherapeutic responsiveness. To maintain cell growth, a continuous flow at 
a rate of 2 microlitres/hour was maintained. The ability to double was seen to be like that of 
petri-dish culture and migration between microwells was prevented. As had previously been 
seen in cancer cell development, three different sub phenotypic clones were isolated in this 
method from the single cells, holoclones, meroclones and paraclones, which each exhibited 
its own morphology and growth rate (58). Each phenotype was then tested against different 
chemotherapeutic agents such as docetaxel with varying response, thus highlighting the 
clinical use of this method to isolate and track the response of a single patient’s cancer cells 
to therapeutic agents, even as the cells may develop (59) .  
 
Furthermore, with regards to therapeutics and novel treatment analysis, a team in 2011 
isolated prostate non-coding serum microRNAs (miRNAs) from humans using a multiplex 
quantitative reverse transcription PCR method. Similar to proteins found in disease and 
normal physiology, miRNAs are thought to be significant biomarkers of pathology, whilst 
allowing analysis of prostate cancer genotypes (32).  After isolation, the miRNAs underwent 
uniplex analysis on a microfluidic chip to analyse the miRNAs further, highlighting oncogenic 
and tumour suppressive miRNAs in untreated prostate cancer patients. This method helped 
to both distinguish healthy patients from those at high risk but also those patients at curable 
stages of prostate cancer. The purpose of this was to allow for a more prostate cancer 
specific biomarker and to permit better individualised patient care based on the analysis (33).  
 
Microfluidics and prostate cancer physiology 
Microfluidics has also been proven to play a key role in understanding high propensity to 
metastasise to bone, which occurs in up to 90% of those patients with metastases (60).  
 
Starting in 2009, a team in Michigan looked at the microenvironment of prostate cancer 
metastasis to bone using microfluid generated spheroids. Spheroids, as sphere shaped 
groupings of cells, act as excellent tumour models and provide reliable therapeutic 
information (61). Using a technique previously to form embryoid bodies, the spheroids were 
formed using microfluidics, to create a 3-dimensional in vivo bone microenvironment (62). 
The spheroid microenvironment, created using osteoblasts and endothelial cells, mimicked 
bone tissue that a metastatic prostate cancer cell could reside in. The prostate cancer cells 
were then transfected with a fluorescent protein to track their numbers within each spheroid 
during the experimental period, during which they were able to survive and proliferate. 
Though the proliferation rate of the cells was reduced as compared to the normal 2-
dimensional in vitro studies, it was thought that this was an effective mimic of what happens 
in vivo. Additionally, the viability of the cells was not affected, and so the behaviour of the 
prostate cells could effectively be studied. In fact, some of the cells lines even died 
comparatively when a monoculture was done in the 3D study environment, revealing that 
the spheroid created by the microfluidic chip has non-additive synergistic effects. The team 
acknowledged that this research may show utility at a later stage for testing of drugs in an in 
vivo like environment (63). 
 
Furthermore, a team in 2014 used a microfluidic platform with multi-photon imaging 
techniques to assess prostate cancer and found that an osteotropic prostate cancer cell line, 
when with bone stromal cells, had increased physiological function. This was detected 
through an increase in fluorescence, likely due to increased cytoplasmic enzyme activity, 
which permitted creation of reactive oxygen species. This increase in reactive oxygen species, 
allowed for an overall increase in protrusive phenotype and potential invasive capacity of the 
prostate cancer cells in the bone environment. In addition to highlighting how bone 
metastases can proliferate, this technique offered multiple advantages in allowing multiple 
assays to be performed on one device, with relative ease and low-cost customisation. 
Microfluidics thus clearly offers vast possibilities for further prostate cancer model design 
and analysis. (64) 
 
Building on attempts to understand prostate cancer in specific environments, a team in 
Arizona developed a partial microfluidic based model of the prostate gland, to create a 
unique 3-dimensional microenvironment. The model used two stacked microchannels 
separated by a porous membrane which allowed long term cell cultivation within a 
microfluidic chip. The membrane permitted the culture of two separate cell populations on 
either side (stromal and epithelial cells), which permitted paracrine signalling without cellular 
crossing. This environment allowed for study of the epithelial stromal interface lining the 
ductal systems of the human prostate gland. The system involved the flow of culture media 
at an appropriate rate to not disturb communication between the two sections, whilst 
optimising growth and differentiation. As a transparent device the microfluidic chip 
permitted bright field and fluorescence imaging throughout. By the end of the experiment, 
groups of cells within the chip appeared to begin to show features resembling prostate tissue 
architecture. The effects of various hormones could be studied throughout the research. 
Though not directly involved in prostate cancer research at this stage, the team were better 
able to understand paracrine and endocrine cross talk within the model which was hoped to 
permit further investigation. This research may therefore hold a key to better understanding 
morphogenesis and disease development, in appropriately recapitulating the biology and 
physiology of the carcinogenic human prostate (65).  
 
Khanal et. al in 2014 undertook more specific research about the prostate cancer 
microenvironment and worked to analyse the effect of hypoxia on prostate cancer. They did 
this through using a microfluidic device to test the susceptibility of cancer cells to the 
chemotherapeutic agent staurosporine. Hypoxia is a known critical feature of the tumour 
microenvironment (66). Analysis on the microfluidic chip offered significant advantages in 
increasing temporal and spatial resolution, ensuring high throughput analysis, as well as the 
ability to sense oxygen via dyes (67). The conclusion of the study was that hypoxic 
preconditioning acted to increase drug resistance with statistical significance, as measured by 
fluorescent staining to identify cellular apoptosis. The apoptotic cells could be sensed as early 
as one hour after drug treatment. The study also highlighted that even just one hour of 
hypoxia is enough to enhance cancer resistance to therapeutic agents. Thus, this microfluidic 
format can be used to assess therapeutic agents in hypoxic environments, as those studies 
performed at a normal oxygen level are likely not a true indicator of chemotherapy effect in 
vivo (68).  
 
A research team in the previous year also looked at the key role of hypoxia in cancer, by 
analysing 8-hydroxy-2’-deoxygyanosine (8-OHdG) as a product of DNA oxidation damage and 
mutation in prostate cancer. 8-OHdG is a chemical product that can be detected in the urine 
as a marker of oxidative stress associated with prostate cancer. A small detection limit of 
5pg/mL was found using their microfluidic device designed for the specific purpose to 
estimate oxidative DNA damage. This device used modified paramagnetic particles with 
monoclonal antibodies to allow for immunoextraction and immunodetection, with 
electrochemical detection of the 8-OHdG determined with 1-naphthol.  As a patient based 
study it was expected that this experimental design will have future clinical application in 
personalised therapies (69).  
 
Looking further at hypoxia, research has shown that the uptake of cancer associated fatty 
acids, such as palmitic acid is increased in hypoxic conditions and can stimulate progression 
of cancer (70). Subsequently, a microfluidic system was created with a Raman microscope to 
optimise real time measurements in variable conditions, to show that uptake of omega 3 
fatty acids such as docosahexaenoic acid reduced the uptake of cancer stimulating fatty acids 
by prostate cancer cells. Microfluidics added to the work in enabling study of the biological 
system in a natural environment, with dynamic flow provided by the microfluidic system to 
permit in vivo physiological conditions (71). This research holds significant value for further 
research analysis in both highlighting the value of hypoxic studies and in understanding 
cancer effects at a cellular level.  
 
Whilst hypoxia can induce significant change in cancer cells, androgens can also induce 
significant change in prostate cancer so that it becomes refractory to further androgen 
therapy, and becomes androgen independent (72). Therefore, research was conducted into a 
comparison of androgen sensitive and insensitive human prostate cancer cells to analyse 
their mechanical properties. In this study, a microfluidic chip was designed to deform tumour 
cells so that they could subsequently be analysed. The team found that androgen insensitive 
prostate cancer cell lines are mechanically stiffer than their androgen sensitive counterparts, 
and these properties can be used as biomarkers for early androgen independent prostate 
cancer identification. Results also suggested that cell size and deformation degree were also 
potential parameters for classifying cell type. It was hypothesised that this change in 
mechanical durability was due to the androgen therapy causing change in the mechanical 
properties of the cell. Though the technique was primarily used to understand how androgen 
deprivation therapy may alter cells so the therapy is no longer effective, it may have further 
applications in suggesting when the therapy is no longer as effective at a cellular level (73). 
 
It can therefore be seen that the use of microfluidics is not limited to detecting prostate 
cancer, but it is also being used to understand how the cancer functions at a cellular level. 
Ultimately, microfluidics will help ensure patients receive optimal treatment based on the 




Looking into the future, microfluidics will likely aid detection of many new-found prostate 
cancer biomarkers. Examples of these include exosomes, found in various body fluids 
including urine, and deemed important cancer biomarkers in liquid biopsy (57, 74). Exosomes 
are endosomal-derived vesicles released from cells, including cancer cells, that contain 
bioactive material, such as RNA, actively extruded from cells (75).  In one study, exosomes 
were found to contain non-coding RNA, miR-409, which was found at high levels in prostate 
cancer cells. Upon release into the tissue environment, miR-409 is able to promote 
intracellular and extracellular changes in normal prostate cells to promote tumour induction 
(76). Furthermore, a study in 2009, analysing the RNA contents of exosomes from prostate 
cancer patients, found that the biomarker PCA3 was overexpressed in prostate cancer 
urinary exosomes (77). Additionally, the research showed that the mere presence of other 
biomarkers such as PSA mRNA could indicate the patients status of treatment (78).  These 
two studies highlight the significant potential of exosomal content analysis in acting as a 
potential cancer biomarker for prostate cancer diagnosis. 
 
As mentioned above, exosomes, likely shed from the urinary tract, have been found in urine 
of patients with prostate cancer. These exosomes from prostate cancer patients have even 
been shown to have a unique lipid composition, so further suggesting their potential as 
cancer biomarkers (79). Work in 2016 highlighted that the lipid content of urinary exosomes 
could be analysed, and significant differences could be seen in the exosomes isolated from 
prostate cancer patients as compared to a normal population. Through use of high 
throughput mass spectrometry, exosomes from prostate cancer could be identified with 93% 
sensitivity and 100% specificity. As this involves urinary exosomes, if such a test were to 
become validated, it would be ideal as a point-of-care test and it is possible that a 
microfluidic chip could be designed to carry out the process  (80).  
 
Aside from their lipid content, the protein content of exosomes in prostate cancer patients 
has also been shown to be unique. A research team based in Norway, compared the protein 
content of urinary exosomes of 16 prostate cancer patients with that of 15 control patients. 
With a high level of sensitivity, this team found that multiple proteins on the exosomes could 
be used as prostate cancer biomarkers, as they were either upregulated or downregulated. 
The team hypothesised that combination testing for these proteins in a multi-panel test had 
the potential for clear identification of prostate cancer patients from control subjects (81).  
We have therefore seen how the RNA, lipid, and protein content of exosomes from prostate 
cancer patients is notably unique and may thus constitute novel prostate cancer biomarkers 
if they can be appropriately detected.  
 
One of the challenges of working with exosomes and other Extracellular Vesicle (EV) subtypes 
is the heterogeneity of the vesicles. Although this may not be as marked for exosomes as 
with microvesicles (or medium-sized EVs) there are still variations in terms of size, 
morphology, lipid composition, even refractive index that need to be considered for isolation 
and enumeration (82). Biofluids may also contain non-EV particulate matter such as 
lipoproteins and protein aggregates. With many avenues now available for isolation of cancer 
specific exosomes however, work has already begun into microfluidic separation of exosomes 
from whole blood samples using acoustic waves, in what is referred to as an acoustofluidic 
platform. This platform was able to achieve high yield results of exosomal separation of 99%. 
However, in this study the team did note that more work was required to ensure exosomes 
obtained have the highest purity (83). Unfortunately, this study was neither a cancer study 
nor did it highlight differentiation between exosomes isolated, so more work would be 
required prior to use of this platform in prostate cancer testing.  
 
Moving on from acoustic separation, an Australian team created a microfluidic device for 
exosome detection using a tuneable alternating current electrohydrodynamic method that 
relied on shear forces. This technique generated flow on the microfluidic chip that enhanced 
capture specificity. Using this method, the team were able to isolate exosomes from cells 
expressing PSA with high specificity and selectivity. Though most of the investigations in this 
study resolved around breast cancer, PSA was also tested for, highlighting the applicability of 
the separation method to prostate cancer (84). It is likely not long before this technique 
could be used to further prostate cancer diagnosis and therapy. 
 
A non-microfluidic mean of exosomal isolation includes the use of the previously mentioned 
surface enhanced Raman Scattering technique for rapid and label free detection of 
exosomes. This technique was able to discriminate between exosomes originating from 
cancer cells and normal cells, based on their SERS spectral patterns, with a sensitivity greater 
than 95%. Combining SERS with chemometrics and machine learning algorithms could 
facilitate the rapid differential diagnostics, treatment-response monitoring and personalised 
medication of the disease. Though the method did not analyse prostate cancer cells 
specifically, it is not far reaching to suggest that microfluidic techniques could be combined 
with SERS to permit prostate cancer exosome detection, given the success of the 
aforementioned methods (85).  
 
For isolation of specific exosome subsets derived from particular cell types, specificity and 
sensitivity can be increased by use of immuno-affinity selection using antibodies conjugated 
to magnetic beads or with an antibody-conjugated surface (86).  
 
The possibility of isolating specific urinary exosomes and therefore of using liquid biopsy 
(with a reduced number of isolation steps compared to conventional methodologies) as a 
way of detecting the presence of malignant cells, will bypass the need for invasive tissue 
biopsies in prostate cancer and simplify screening of those at risk of developing disease. As 
research continues into exosomes and their utility as cancer biomarkers, it is likely that 




Based on the vast number of research studies undertaken in the last few years, applications 
of microfluidics in prostate cancer are greatly increasing, most likely driven by an 
international drive to prevent mortality and morbidity. The cost-effective nature of 
microfluidics, together with the easily modifiable simple device design makes it an ideal 
candidate for a variety of uses in treating and researching prostate cancer.  
 
This review has demonstrated multiple routes of prostate cancer detection in the form of 
CTCs, demonstrated that point-of-care testing will aid future rapid diagnosis of many 
conditions, and that microfluidics should enable this to happen at an affordable price. 
Furthermore, microfluidic testing on cancer cells to highlight their chemotherapeutic 
susceptibility and physiology will also play a crucial role moving forward.  
 
Unfortunately, prostate cancer morbidity and mortality is increasing internationally. 
However, through ongoing microfluidic research, it is hoped that patient diagnosis and 
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Key Points 
• Use of microfluidic systems in the diagnosis and management of prostate cancer is 
rapidly increasing to enhance the capacity for point-of-care testing. 
• Prostate specific antigen can be detected by microfluidic techniques but problems 
remain with cancer specificity of detected samples, though multiple avenues are 
available to circumvent the challenge posed. 
• Circulating tumour cells can also be detected by microfluidic techniques to 
appropriately detect cells based on physical properties as well as antigen markers. 
• Once isolated, cells can be analysed to assist in better understanding the physiology 
and management of prostate cancer in a wide variety of ways. 
• Future directions for prostate cancer detection with microfluidics include exosomal 
detection which will also aid in understanding of the cancer. 
 
 
Table 1. TRL (Technology Ready Level) and definitions of each level. 
 
TRL Definition 
1 Scientific research is beginning, and those results are being translated into future 
research and development. 
2 The basic principles have been studied and practical applications can be applied to 
those initial findings. 
3 Generally, both analytical and laboratory studies are required at this level to see if 
a technology is viable and ready to proceed further through the development 
process.  
4 Once the proof-of-concept technology is ready, the technology advances to TRL 4. 
During TRL 4, multiple component pieces are tested with one another.  
5 A technology that is at TRL 5 is identified as a breadboard technology and must 
undergo more rigorous testing than technology that is only at TRL 4.  
6 The technology has a fully functional prototype or representational model. 
7 TRL 7 technology requires that the working model or prototype be demonstrated 
in a clinical environment.  
8 TRL 8 technology has been tested and "clinically proven" and it is ready for 
implementation into an already existing technology or technology system.  
9 When a technology has been "clinically proven" and widely implemented, it can be 
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2019 (87) 
small RNAs (<30 
nt) 
10 ml of sera 
from volunteers 
cluster amplification with 
bridge PCR 
(Solexa, Illumina) 
N/a 9 Identity of each base of 
a cluster is read off 
from sequential images 
Chen et al. 
2008 (32) 
miR-19a, -20b, -
24, -26b, -30c, -
93, -106a, -223, -







from 38 donors: 
9 healthy, 9 low, 
11 intermediate, 
9 high CARPA 
scores 
dRT-PCR: thermal cycling, 
image  
acquisition, analysis 
N/a 9 TaqManProbe using 
Fluidigm Biomark 
platform 96 x 96 arrays 
Moltzahn et 
al. 2011 (33) 
PSA/0.5 ng/mL human serum Incubation and detection 30 min 4 Amperometric 
Sandwich 
Immunoassay, 
secondary Ab coupled 
to HRP 
Panini et al. 
2008 (20) 
PSA/10 pg/mL PSA-spiked 
buffer  
immobilisation, detection 7 s 3 Cyclic voltammetry, 
competitive 
displacement 
of GOx-PSA from 
immonopatterned 
nanoelec. 
Triroj et al. 
2010 (9) 
PSA/0.84 pg/mL human serum immobilisation, detection 20 s 4 Chronamperometry, 
immunoassay magnetic 
beads PSA-specific Ab1 
(M-Ab1), and Ab2-HRP 
Chen et al. 
2019 (21) 
PSA/10 ng/mL human serum immobilisation, detection < 1 hr 4 Love-wave Inter 
Degitated Sensor using 
aptamers as capture 
probe for PSA 
Zhang et al. 
2015 (22) 
PSA/0.31 pg/mL human serum 
from 7 donors 
immobilisation, detection 20 min 4 rGO-BiFeO3-based 
photo electrochemical 
sensing magnetic 
controlled system  
Zhou et al. 
2018 (23) 
PSA/0.04 ng/mL whole blood 
from 3 patients 
manual reagent priming of 
capillaries (MCF), detection 
phone 
13 min 4 Fluorescent assay using 




al. 2015 (25) 
fPSA, tPSA / <0.1 
ng/mL 
human serum 
from 5 clinical 
samples 











microdroplet channels  
Gao et al. 
2018 (29) 




5 min 6 Sandwich 
Immunoassay based on 
SERS nanotags,  
PSA biomarkers and 
magnetic beads 
Gao et al. 
2019 (31) 
PSMA on PCTCs/ 









immunocapture (GEDI)  
n/a 4 FITC-conjugated J591 









1 mL of blood 
spiked with 
LNCaP cells 




29 min 5 Trypsin, followed by 
conductivity cell count 
on-chip 
Dharmasiri et 
al. 2009 (42) 
PSMA in sln. or 
PSMA+ cells 
serum from mice Capture on amino 
functionalised gold 
nanoparticles with Abs 
onto ITO electrodes  
10 min 4 Differential Pulse 
Voltammetry with a 
redox couple 
[Fe(CN)6]3–
/[Fe(CN)6]4–   
Seenivasan 








24 hr 3 Staining on-chip, 
fluorescent analysis, 
off-chip enumeration  
Kirby et al. 
2012 (45) 
CTCs human PCa cells 
spiked in mouse 
blood 
isolation and drug testing 
on a single cell, size-based 
separation, e-trap 
> 1 hr 3 Fluorescence m-nt of 
drug accumulation 
(DNR ± FITC) 
Khamenehfar 
et al. 2015 
(47) 
CTCs 2 mL blood from 
50 patients, 
localised PCa 
Separation based on size, 
deformability using 
microfluidic ratchet for 
enrichment 













selective CTC isolation 
capture onto J591 Ab 
n/a 3 DEP characterisation of 
cells 
Huang et al. 
2013 (52) 
CTCs whole blood (7.5 
mL) from 22 
patients with 
stage IV PCa 
size-based separation and 
recovery of cells using 
inertial microfluidics 
< 1 hr 4 Off-chip 
immunochemistry, 
enumeration and 
mutation analysis  
Renier et al. 
2017 (54) 
CTCs / 72.5 to 
















et al. 2012 
(55) 
CTCs murine whole 
blood spiked 
early stage CTC enrichment 
through trapping into 
30 min 
for 1.2 
3 On-chip microscopy 
and enumeration of 








cells that express GFP 






LNCaP diluted in 
PBS (1:9, vol/vol) 
















PC3 cell grown 
onto 8x8 array 
concentration gradient 
formation, integrated 
pumps, valves for cell 




5 Immunostaining and 
microscopy on-chip 








gravitational cell seeding 
and flow, cell migration ctrl 
geometries, drug screening  
6 days 
culture 
5 Imaging of the growth 
chambers 









(28 wells / chip) 
perfusion 3D cell culture 





4 Imaging phase-contrast 
and fluorescent 
microscopy from each 
well 









separated by a 
membrane 


































7 BioFlux chip coupled 
with a Raman 
microscope 









N/a 4 High-speed imaging & 
Image analysis 


















Figure 1. Antibody capture on microfluidic device.  
(A) Schematic illustration of the dual-antibody-functionalized microfluidic device where antibodies 
against prostate-specific membrane antigen (anti-PSMA) and epithelial cell adhesion molecule 
(anti-EpCAM) are used to capture CTCs. Shown are fluorescent micrographs of CTCs captured from 
the LnCAP cell spiked normal blood samples (50). Reprinted with permission from Yin C, Wang Y, Ji 
J, Cai B, Chen H, Yang Z, et al. Molecular Profiling of Pooled Circulating Tumor Cells from Prostate 
Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device. Anal Chem. 
2018;90(6):3744-51. Copyright 2018 American Chemical Society. 
(B) Schematic representation of device functionalization whereby gold (Au) microelectrodes are 
modified with biotinylated bovine serum albumin (Biotin-BSA), streptavidin and capture antibody 
(eg: anti-PSA). Following exosome capture a horseradish peroxidise conjugated detection antibody 
(HRP-Detection Ab) is introduced followed by a chromogenic substrate (TMB). The resultant 
colorimetric reaction is visible with the naked eye and can be measured with a spectrophotometer 
(84). Reprinted with permission from Vaidyanathan R, Naghibosadat M, Rauf S, Korbie D, 
Carrascosa LG, Shiddiky MJ, et al. Detecting exosomes specifically: a multiplexed device based on 
alternating current electrohydrodynamic induced nanoshearing. Anal Chem. 2014;86(22):11125-






Figure 2. Continuous flow separation microfluidic devices.  
(A) Schematic representation of three microfluidic components of the CTC-iChip. Input of blood 
premixed with magnetic beads is introduced alongside buffer. Hydrodynamic filtration occurs by 
deterministic lateral displacement. Inertial sorting and magnetophoresis results in CTC separation 
and isolation (49). 
(B) Schematic illustration of integrated acoustofluidic platform for direct isolation of exosomes from 
whole (unlabelled) blood. The tilt of the modules allows size-dependant lateral deflection of 
particles by acoustic forces. Two surface acoustic wave modules act in sequence. Unit 1 separates 
larger cells including red blood cells (RBCs), white blood cells (WBCs) and platelets from whole 
blood. Unit 2 isolates smaller exosomes from remaining extracellular vesicles (83). 
 
